针刺联合言语康复训练治疗脑卒中后构音障碍的系统评价与Meta分析
针刺联合言语康复训练较单纯言语康复可能提高临床有效率(n=1685;RR=1.37;95%CI [1.29, 1.46];P<0.01;I²=34%;17项研究,低证据质量)。结论认为联合治疗可能改善卒中构音障碍患者的总有效率,但需更多设计严谨的RCT证实。
要点
- 针刺联合言语康复训练可能提高脑卒中后构音障碍的临床有效率。
- 该结论基于低证据质量,需更多严谨RCT验证。
- 主要结局采用Frenchay构音障碍评定(FDA)评估临床有效率。
核心结论
- 针刺联合言语康复训练可能改善脑卒中构音障碍患者的总有效率。
- 证据确定性为低,需更多设计严谨、结局指标经效度验证的RCT确认。
研究设计与样本
- 采用Cochrane偏倚风险工具评估偏倚风险,采用GRADE评估证据确定性。
主要发现
- 针刺联合言语康复训练对比单纯言语康复治疗,有效率(n=1685;RR=1.37;95%CI [1.29, 1.46];P<0.01;I²=34%;17项研究;低证据质量)。
关键数值与推荐
- 主要结局指标为临床有效率,采用Frenchay构音障碍评定(FDA)工具评估。
临床怎么用
- 对脑卒中后构音障碍患者,可考虑在言语康复训练基础上联合针刺治疗以改善有效率。
- 应用该联合方案时应知晓当前证据质量较低,需结合患者具体情况个体化决策。
局限性
- 证据确定性为低(GRADE低证据质量)。
- 原文指出需要更多设计严谨且采用效度验证结局指标的RCT来确认证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The evidence of Acupuncture combined with speech rehabilitation training for post-stroke dysarthria is insufficient and there is no consensus on its efficacy. METHODS: We searched seven Chinese and English medicine databases for randomized controlled trials (RCTs) from their inception to November 2019. The primary outcome measure was the clinical response rate, assessed with the Frenchay Dysarthria Assessment (FDA) tool. We assessed risk of bias using the Cochrane risk-of-bias tool. We used GRADE to assess the certainty of evidence (CoE). RESULTS: Thirty studies were included in this systematic review, 23 of which were pooled in meta-analysis. Acupuncture combined with speech rehabilitation training is likely beneficial for was response rate (n = 1685; RR = 1.37; 95% CI [1.29, 1.46], P < 0.01, I 2 = 34%; 17 studies, low CoE) compared to speech rehabilitation treatment alone. CONCLUSION: The combination of acupuncture and speech rehabilitation training may improve total response rate of stroke patients with dysarthria. However, more RCTs with rigorous study design and validated outcome measures are needed to confirm the evidence.
引用
- Xie Q, Chen X, Xiao J, et al. Acupuncture combined with speech rehabilitation training for post-stroke dysarthria: A systematic review and meta-analysis of randomized controlled trials. Integr Med Res. 2020. PMID: 32637314. doi:10.1016/j.imr.2020.100431
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。